These results suggested treatment with rapamycin (2 mg/kg/day) for two weeks did not block mTORC2 assembly, nor did it reduce the levels of mTORC2 below those needed to maintain AKT/PKB signaling in this pathophysiologic progress of cirrhotic portal hypertension. Here, AKT1 is linked to liver disorder.